Percentage of Rx drugs prescribed to multiple sclerosis patients 2013

This statistic displays the percentage of disease-modifying therapies (DMTs) prescribed to multiple sclerosis patients as of 2013, as reported by neurologists. As of that year, 5.2 percent of patients were prescribed fingolimod.

Percentage of disease-modifying therapies (DMTs) prescribed to multiple sclerosis patients as of 2013*

Mean percentage of patients prescribed medication
Fingolimod5.2%
Glatiramer acetate28.7%
IM IFN β-1a18.7%
SC IFN β-1a18.8%
IFN β-1b20.6%
Other**7.7%
No DMTs5.5%
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

2014

Region

United States

Survey time period

December 2012 to January 2013

Number of respondents

102 respondents

Special properties

general neurologists and MS specialists

Method of interview

Online survey

Supplementary notes

* Mean percentage. As reported by neurologists. Abbreviations: IM, intramuscular; IFN, interferon; SC , subcutaneous; DMTs, disease-modifying therapies.
** Includes patients on natalimumab (6.6%) and other medications (azathioprine, cladribine, cyclophosphamide, daclizumab, intravenous immunoglobulin, methotrexate, mycophenolate mofetil, naltrexone, rituximab, corticosteroids, teriflunimide [1.1% combined]).

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Hospitals in Germany"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.